Search | Clinical Trials Finder

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: Hidradenitis Suppurativa
Interventions: Electronic Reporting, Adalimumab; Other · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Elena Gonzalez Brant, MD; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Hidradenitis Suppurativa
Interventions: Ertapenem; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Pelashield Painguard; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hidradenitis Suppurativa
Interventions: MEDI8968, Saline; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more

Conditions: Hidradenitis Suppurativa
Interventions: Mediterranean Diet Counseling, Mediterranean Food Support; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hidradenitis Suppurativa
Interventions: Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Hidradenitis Suppurativa
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 15
States / cities: San Diego, California • Whittier, California • Coral Gables, Florida + 11 more

Conditions: Hidradenitis Suppurativa, Hidradenitis
Interventions: Low dose Radiotherapy; Radiation
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 20 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hidradenitis Suppurativa
Interventions: Ritlecitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 25 more

Conditions: Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
Interventions: Myriad Matrix™ and Myriad Morcells™; Device
Lead sponsor: Aroa Biosurgery Limited; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 11 more

Conditions: Hidradenitis Suppurativa
Interventions: Battlefield Acupuncture, Sham Acupuncture; Procedure
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Dearborn, Michigan

Conditions: Hidradenitis Suppurativa
Interventions: 1320nm Nd: YAG nonablative laser; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more

Conditions: Hidradenitis Suppurativa, Hyperhidrosis
Interventions: Botulinum toxin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Contact Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: BFB759, Placebo for BFB759; Biological · Other
Lead sponsor: Bluefin Biomedicine, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Encino, California • Santa Monica, California + 28 more

Conditions: Hidradenitis Suppurativa
Interventions: Brivekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Northridge, California + 12 more

Conditions: Hidradenitis Suppurativa
Interventions: secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more

Search by objective public record fields.

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa Patient Experience With Humira Treatment

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Mediterranean Dietary Intervention for HS

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

Myriad™ Augmented Soft Tissue Reconstruction Registry

Battlefield Acupuncture for Pain in Hidradenitis Suppurativa

To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Targeting Nociceptors in Hidradenitis Suppurativa

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).